Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

The Affordable Care Act is shifting the economic risks of care from the payors to the providers, and medtech companies will be forced to find new sales and distribution channels, new ways of defining clinical and economic benefit, and new offerings wrapped around devices to enhance both their clinical and economic value. At the IN³ meeting in October 2013, executives from both the payor and provider communities discussed how medtech companies should respond to these new dynamics.